|
| |
Biota (ASX:BTA) announces Relenza royalties of AU$8.9M for 3 months ended 30
June 2009
Melbourne, Australia – 23rd July 2009: Biota Holdings (ASX:BTA) today
announced that it had received written notification from GlaxoSmithKline (GSK)
that indicative royalties for the three months ended 30 June 2009, were $8.9m on
Relenza sales of $122.5 million.
Royalties for the complete 2009 financial year total $45.0 million on Relenza
sales by GSK of $638.7 million compared to $20.5 million and $304.4 million,
respectively in F2008.
Biota’s CEO Peter Cook reiterated there is a time lag between an order being
placed and a recorded sale on the shipment of goods. The significant government
stockpile orders placed after the swine flu outbreak in late April 2009, would
appear as sales in future quarters.
About Biota
Biota is a leading antiinfective drug development company based in Melbourne
Australia, with key expertise in respiratory diseases, particularly influenza.
Biota developed the firstinclass neuraminidase inhibitor, zanamivir,
subsequently marketed by GlaxoSmithKline as Relenza. Biota research
breakthroughs have included a series of candidate drugs aimed at treatment of
respiratory syncytial virus (RSV) disease, licensed to AstraZeneca and novel
nucleoside analogues designed to treat hepatitis C virus (HCV) infections,
licensed to Boehringer Ingelheim. Biota has clinical trials underway with its
lead compound for human rhinovirus (HRV) infection in patients with compromised
respiration or immune systems. In addition, Biota has a key partnership with
Daiichi Sankyo for the development of second generation influenza antivirals.
Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.
*Further information available at
www.biota.com.au
Investor / Analyst Enquiries
Biota Holdings Limited
CEO Peter Cook
T: +61 3 9915 3720
CFO Damian Lismore
T: +61 3 9915 3721
European Media Enquiries
College Hill Life Sciences
Adam Michael, Justine Lamond & Benjamyn Tan
T: +44 (0)20 7866 7857
biota@collegehill.com
| |
|
